Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (2545)	11/3/2005 7:51:22 PM
From: software salesperson	Respond to of 3044

11/2/05 analyst day highlights P 1 / 2 data V + Rev at Ash Updated Apex survival data at Ash V re-treatment data 2nd ½ ‘06 Mantel cell trial completed now; snda in 2nd ½ ‘06 Interim V data for relapsed follicular lymphoma at Ash Encouraging, early SWOG P 2 front line nsclc data; V + gemcitabine + carboplatin; final data 1st ½ ‘06 2nd line nsclc P 1 / 2 V + tarceva started 2nd line nsclc P 1 / 2 V + alimta planned soon BAC single agent P 2 ongoing 2 of the new molecules have applicability to cancer and inflammation; ccr1- - inflammation, MM and bone metastases; ikkß - - inflammation, lymphoma, myeloma, chemotherapy-resistant solid tumors believes 02 is gut-specific and won’t see immune system turned off in other end organs initiated P 1 with 8054, aurora A kinase oral inhibitor- - colorectal, solid and hematological tumors; uses a novel scaffold with possible applications for many other kinases 2nd generation proteasome inhibitor in clinic in 2007 0415 oral ikkß inhibitor - - preclinical activity in RA, MS, COPD; in clinic 2nd ½ 2006 data on V in ovarian and prostate cancers will be available by year end talking to NIH about trials for V in stroke SWOG nsclc study data will be available at asco in may Re: competition, V has always added value in combo Re: specificity of ccr2, might you be blocking something else? - - that’s why we wanted to try many indications early. Possible next steps- - scleroderma P 2a --> P 3; all other indications would go to P 2b next V targets a different subset of BAC patients than tarceva and iressa; V will be active in patient population that does not require a egfr mutation We are in the process of approving an investigator-initiated sponsored trial for V + avastin 02 is a high priority for us in UC since it has shown a clinical response in both UC and Crohn’s; dna passed on it as a portfolio decision initiatives that will increase V sales - - adding more salespeople; adding more cycles; everest retreatment could propel sales like rituxan; front-line mm; nhl/mantel cell;nsclc V is multiple drugs in one; V inhibits multiple mechanisms in one drug and that’s why with V we don’t see significant acquired resistance in hematological malignancies; V is a stabilizer of tumor suppressors, has anti-vegf activity, inhibits ikk through nfkb stabilization of ikb, and has an effect on cyclins It may be that the reason that V hasn’t worked on all tumor types so far is not because V is targeting the wrong key mechanisms; rather, V may not be penetrating enough; we’re still working on this idea Impressions: the SWOG lung cancer data sounded good strong presentation and discussion of r&d efforts by tepper and schenkein; did their r&d efforts just need more time? It’s probably just a matter of time before they do another deal with jnj for 0415 and/or 2nd generation V molecules were divided into those that were biologically active vs. those that needed proof of concept; the order presented was: V, 02, 518, 2704; and 8054, 1202, 3897 and 0415 sales